You are here: Industry Insights > ViiV Healthcare

News List

FDA Approves Apretude Drugs
December 27, 2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi) as shareholders...
FDA approves ViiV Healthcare’s Apretude for HIV prevention Pharmaceutical-Business-Review
December 22, 2021
The long-acting injectable is indicated for use in adults and adolescents who are at risk of sexually acquiring HIV and test negative for HIV-1 before initiation.
US FDA approves ViiV Healthcare’s Cabenuva as complete long-acting regimen for HIV treatment expresspharma
January 22, 2021
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine to maintain viral suppression with 12 dosing days per year.
European Commission approves dispersible tablets to treat paediatric HIV europeanpharmaceuticalreview
January 14, 2021
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
First long-acting HIV treatment approved in Europe europeanpharmaceuticalreview
January 05, 2021
The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease.
EU nod for first long-acting HIV injectable treatment pharmatimes
December 22, 2020
The European Commission (EC) has authorised Janssen’s Rekambys (rilpivirine injection) in combination with ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) to treat HIV-1 infections in adults who are virologically suppressed.
ViiV’s cabotegravir scores breakthrough designation for HIV prevention pharmatimes
November 19, 2020
GlaxoSmithKline subsidiary ViiV Healthcare has announced that its long-acting injectable cabotegravir has scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for HIV prevention.
ViiV’s long-acting HIV drug beats standard of care in prevention study pharmatimes
November 12, 2020
ViiV Healthcare has announced that its long-acting injectable cabotegravir for HIV prevention demonstrated superiority compared to the current standard of treatment for women.
ViiV’s two-drug HIV regimen demonstrates long-term efficacy pharmatimes
October 10, 2020
ViiV Healthcare has released long-term data for its two-drug regimen of dolutegravir plus lamivudine, which continued to offer non-inferior efficacy compared to a three-drug regimen in HIV.
ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato pharmaceutical-business-review
August 11, 2020
Specialist HIV company ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its Dovato (dolutegravir/lamivudine) as a complete regimen to treat HIV-1 infection.

Previous page 1 2 3 Next page